A statement released earlier today by H.C. Wainwright about vTv Therapeutics (NASDAQ:VTVT) bumps the target price to $13.00
- Updated: September 25, 2016
H.C. Wainwright bumped up the target of vTv Therapeutics (NASDAQ:VTVT) to $13.00 stating a potential upside of 0.81%.
On Monday August 24, 2015, Piper Jaffray released a statement for vTv Therapeutics (NASDAQ:VTVT) bumped up the target price from $0.00 to $24.00 that suggested an upside of 1.71%.
Boasting a price of $7.17, vTv Therapeutics (NASDAQ:VTVT) traded 3.02% higher on the day. With the last stock price close up 23.35% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. vTv Therapeutics has recorded a 50-day average of $6.05 and a two hundred day average of $5.81. Trading volume was up over the average, with 38,321 shares of VTVT changing hands over the typical 37,555
Recent Performance Chart
vTv Therapeutics has with a one year low of $4.84 and a one year high of $8.22 and has a market capitalization of $0.
General Information About vTv Therapeutics (NASDAQ:VTVT)
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.